August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
August 29th 2025
New authorization limits shots to adults ≥65 and individuals with underlying health conditions, with ACIP set to review guidance and insurance coverage implications.
August 22nd 2025
New data show consistent late-summer and winter surges, reinforcing the need for seasonal vaccine timing and focused protection for high-risk groups.
August 22nd 2025
STOP-PASC substudy results find digital biometrics align with symptom burden, supporting their use as objective measures in long COVID research.
August 21st 2025
First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.
Moderna Begins Phase 3 Trial for its Influenza-COVID-19 Vaccine
October 26th 2023The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.
Read More
CDC ACIP Votes to Recommend Updated mRNA COVID-19 Vaccines
September 12th 2023The federal agency’s Advisory Committee on Immunization Practices (ACIP) recommendation was to authorize and approve the updated 2023-2024 (monovalent, XBB containing) COVID-19 vaccines for persons 6 months of age and older.
Read More
EMA Recommends Updated Pfizer-BioNTech COVID-19 Vaccine
September 2nd 2023The European Medicines Agency (EMA) based its decision on preclinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine generates an improved response against multiple XBB-related sublineages, including XBB15, XBB116, XBB23, and EG51.
Read More
COVID-19's Impact on Alzheimer's: Uncovering 2 Years of Mortality Trends
July 17th 2023This study found a substantial increase in Alzheimer's-related deaths during the initial year of the pandemic due to limited access to healthcare, social isolation, and disrupted care routines. However, the second year brought positive developments with prevention strategies and vaccinations, leading to a substantial decline in excess deaths.
Read More
COVID-19 Vaccines Bridge Socioeconomic Disparities in Pandemic Impact, CDC Study Shows
July 13th 2023This study analyzed 81 communities in Los Angeles and found that once vaccines became widely available, there was no significant difference in COVID-19 incidence between communities of varying income levels.
Read More
2 Commerce Drive
Cranbury, NJ 08512